Liver transaminase levels alone could not be the optimal method to estimate hepatic safety after statin administration in patients with chronic kidney disease
- PMID: 21742076
 - DOI: 10.1016/j.ahj.2011.04.024
 
Liver transaminase levels alone could not be the optimal method to estimate hepatic safety after statin administration in patients with chronic kidney disease
Comment on
- 
  
  Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.Am Heart J. 2010 Nov;160(5):785-794.e10. doi: 10.1016/j.ahj.2010.08.012. Epub 2010 Sep 18. Am Heart J. 2010. PMID: 21095263 Clinical Trial.
 
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
